Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors

24 Mar 2021

Abstract excerpt

Immune Checkpoint Inhibitors and Tumor Mutational Burden The FDA has approved immune checkpoint inhibitors for solid tumors of any histologic origin with more than 10 mutations per megabase of DNA....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer Immunotherapy and Biomarkers
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33761214
DOI: 10.1056/nejmc2031965

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Spectrum of Benefit from Checkpoint Blockade in Hypermutated TumorsPMID 33761214Read ↗

Hypermutated Tumors and Immune Checkpoint Inhibition.Semantic proximity Read ↗

The status of tumor mutational burden and immunotherapySemantic proximity Read ↗

Dose-Dependent Effect of Tumor Mutation Burden on Cancer Prognosis Following Immune Checkpoint Blockade: Causal Implications.Semantic proximity Read ↗

Mutational Landscape and Sensitivity to Immune Checkpoint Blockers.Semantic proximity Read ↗

Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.Semantic proximity Read ↗

Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor ImmunotherapySemantic proximity Read ↗

Interplay between Tumor Mutational Burden and Mutational Profile and its effect on overall survival: A Post Hoc Analysis of Metastatic Patients Treated with Immune Checkpoint InhibitorsSemantic proximity Read ↗

Hypermutation, Mismatch Repair Deficiency, and Defining Predictors of Response to Checkpoint Blockade.Semantic proximity Read ↗

Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in CancerSemantic proximity Read ↗

Tumor Mutation Burden and Cancer Treatment.Semantic proximity Read ↗

TMBpred: A bioinformatics tool for precise prediction of the Tumor Mutation Burden in 14 cancer typesSemantic proximity Read ↗

Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.